The score is primarily supported by improved 2024 financial performance (profitability, cash generation, and lower leverage). It is held back by mixed technicals (below the 200-day average and slightly negative MACD) and weak/unclear valuation signals due to a negative P/E and no dividend yield.
Positive Factors
Return to Profitability
A return to material profitability and a ~48% net margin in 2024 indicates the business can generate economic profit at current scale. Durable profits improve reinvestment capacity for R&D/commercialization, support creditor confidence, and reduce reliance on dilutive financing if maintained.
Positive Cash Generation
Sustained positive operating and free cash flow strengthens liquidity and funds operations or growth without external capital. For a small biotech, this materially lowers refinancing risk, enables incremental product development or commercialization spending, and supports smoother operations over months.
Improved Leverage and Returns
Meaningful reduction in leverage and a positive ROE improve solvency and financial flexibility. Lower leverage reduces interest burden and covenant pressure, enabling management to pursue strategic partnerships or capex with less dilution risk and a stronger balance sheet cushion.
Negative Factors
Small, Volatile Revenue Base
A small and volatile revenue base undermines the durability of margins and cash flow; sharp swings (deep declines in prior years and a modest rebound) increase execution risk, limit scale economies, and make multi-quarter forecasting and reinvestment planning more uncertain.
Short Track Record of Positive Results
While 2024 improved, prior multi-year losses and intermittent negative cash flow indicate limited consistency. A short track record of profitability raises the chance that recent gains are cyclical, making long-term capital allocation and product commercialization riskier until multi-year stability is demonstrated.
Material Absolute Debt for Size
Despite improved leverage ratios, absolute debt remains material relative to a small revenue base. This can constrain R&D or commercialization spending, increase refinancing risk if revenue dips, and leave less room to absorb setbacks without resorting to dilutive or costly external financing.
Plant Advanced Technologies SA (ALPAT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€7.76M
Dividend YieldN/A
Average Volume (3M)388.00
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,132,326
10 Day Avg. Volume379
30 Day Avg. Volume388
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.44
Price to Sales (P/S)6.86
P/FCF Ratio6.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Plant Advanced Technologies SA Business Overview & Revenue Model
Company DescriptionPlant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include PAT Plant Milking that produces active extracts through plant stimulation and living-root exudation while preserving plants; PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes; and PAT Friday, a recombinant protein expression system using natural protein excretion system of genetically modified carnivorous plants to produce outside their leaf in a sterile closed pitcher. The company was founded in 2005 and is headquartered in Vanduvre-lès-Nancy, France.
How the Company Makes Moneynull
Plant Advanced Technologies SA Financial Statement Overview
Summary
2024 shows a meaningful turnaround with strong profitability, improved leverage, and solid operating/free cash flow. The score is capped by the small revenue base and historically volatile results, including sustained losses and weak/negative cash flow in 2020–2022.
Income Statement
66
Positive
Profitability improved materially: 2024 returned to solid positive earnings (net margin ~48%) and positive operating profit after a loss in 2023, with revenue also rebounding (+~15% in 2024). However, the revenue base remains small and growth has been volatile (sharp decline in 2023), and prior years (2020–2022) show sustained losses and negative margins, which lowers confidence in durability.
Balance Sheet
64
Positive
Leverage has meaningfully improved versus 2021–2022: debt-to-equity is ~0.37 in 2024 (down from ~1.08 in 2022), supported by a larger equity base. Returns also turned positive in 2024 (ROE ~10%). The main weakness is the company’s history of negative returns (2020–2022) and still-material absolute debt levels, which can matter for a smaller revenue company.
Cash Flow
74
Positive
Cash generation is a relative strength: 2024 delivered strong positive operating cash flow (~2.5m) and free cash flow (~2.1m), with free cash flow exceeding 2023 and closely tracking earnings (free cash flow to net income ~0.83). The key risk is consistency—cash flow was minimal/negative in 2020–2022 and some 2023 coverage metrics are not available, so the track record is shorter than ideal.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 03, 2026